Peregrine Pharmaceuticals, Inc.

Patent issued for compounds that target cancer drug delivery

Published in Cancer Law Weekly, October 2nd, 2004

Peregrine Pharmaceuticals, Inc., (PPHM) announced the grant of a new patent for the development of novel compounds that deliver cancer drugs directly to tumor blood vessels to enhance standard anticancer therapy.

Compounds covered by the new patent include methods for treating cancer using Vascular Targeting Agents (VTAs) that bind to tumor blood vessels combined with standard cancer therapies including radiotherapy and chemotherapy.

These novel VTA compounds may be directed to targets included in Peregrine's Anti- Phospholipid Therapy (APT) platform to enhance the anti-tumor effects of standard anticancer therapies without harming normal, healthy...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Law Weekly

Source: Cancer Law Weekly (2004-10-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry